Zbigniew Nowecki

9.9k citations
119 papers · 2.8k · h-index 28

Impact in

  • Gastroenterology top 0.5%
    • Gastrointestinal Tumor Research and Treatment
  • Oncology top 1%
    • Cutaneous Melanoma Detection and Management
    • HER2/EGFR in Cancer Research
    • Cancer Immunotherapy and Biomarkers

Papers in

Co-authors
Piotr Rutkowski (46 shared papers)W. Ruka (29 shared papers)Anna Nasierowska‐Guttmejer (13 shared papers)Wanda Michej (13 shared papers)Urszula Grzesiakowska (11 shared papers)Janusz A. Siedlecki (15 shared papers)Wirginiusz Dziewirski (12 shared papers)Alexander C. J. van Akkooi (7 shared papers)
Journals
Journal of Clinical Oncology (20 papers)Annals of Oncology (15 papers)Annals of Surgical Oncology (8 papers)Cancer Research (7 papers)Cancers (5 papers)
Partner nations
PolandUnited StatesSouth Korea

In The Last Decade

Zbigniew Nowecki

105 papers receiving 2.7k citations

Peers

Zbigniew Nowecki
Comparison fields: 5 of 75
  • Gastroenterology 689
  • Oncology 1.5k
  • Pulmonary and Respiratory Medicine 714
  • Cancer Research 258
  • Immunology 300
Replace W. Ruka with:
W. Ruka Poland
Johannes H. W. de Wilt Netherlands
Amy Harlow United States
Alexander N. Shoushtari United States
Yoshikazu Uenosono Japan
Frédéric Chibon France
Iwona Ługowska Poland
Claudia Le United States
Jaclyn F. Hechtman United States
Maria Cristina Montesco Italy
Zbigniew Nowecki relative to W. Ruka Poland W. Ruka's profile →
Citations per field
00.5×5×10×15×20×25×
W. Ruka · 1×
Citations per year

Countries citing papers authored by Zbigniew Nowecki

Since Specialization
Citations

This map shows the geographic impact of Zbigniew Nowecki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zbigniew Nowecki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zbigniew Nowecki more than expected).

Fields of papers citing papers by Zbigniew Nowecki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zbigniew Nowecki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zbigniew Nowecki. The network helps show where Zbigniew Nowecki may publish in the future.

Co-authors

The 25 scholars most cited alongside Zbigniew Nowecki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Zbigniew Nowecki Line = papers co-authored together Zbigniew Nowecki links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 119 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor
Annals of Surgical Oncology ·Piotr Rutkowski, Zbigniew Nowecki, Wanda Michej, Maria Dȩbiec‐Rychter, Agnieszka Woźniak, Janusz Limon, Janusz A. Siedlecki, Urszula Grzesiakowska, Michał Kąkol, Czesław Osuch, Marcin Polkowski, Stanisław Głuszek, Zbigniew Żurawski, W. Ruka
2007214
2
Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients
Annals of Surgery ·Alexander C. J. van Akkooi, Zbigniew Nowecki, Christiane Voit, Gregor Schäfer-Hesterberg, Wanda Michej, Johannes H. W. de Wilt, Piotr Rutkowski, Cornelis Verhoef, Alexander M.M. Eggermont
2008187
3
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate
Journal of Surgical Oncology ·Piotr Rutkowski, Zbigniew Nowecki, Paweł Nyckowski, Wirginiusz Dziewirski, Urszula Grzesiakowska, Anna Nasierowska‐Guttmejer, Marek Krawczyk, W. Ruka
2006149
4
Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria
Journal of Clinical Oncology ·Augustinus P. T. van der Ploeg, Alexander C. J. van Akkooi, Piotr Rutkowski, Zbigniew Nowecki, Wanda Michej, Angana Mitra, Julia Newton‐Bishop, Martin Cook, Iris M. C. van der Ploeg, Omgo E. Nieweg, Mari F.C.M. van den Hout, Paul A.M. van Leeuwen, Christiane Voit, F Cataldo, Alessandro Testori, Caroline Robert, Harald J. Hoekstra, Cornelis Verhoef, Alan Spatz, Alexander M.M. Eggermont
2011146
5
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
Journal of Clinical Oncology ·Javier Cortés, David W. Cescon, Hope S. Rugo, Zbigniew Nowecki, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, Esther Holgado, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gökmen, Sherene Loi, Zifang Guo, Jing Zhao, Gursel Aktan, Vassiliki Karantza, Peter Schmid
2020139
6
Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes
European Journal of Surgical Oncology ·Piotr Rutkowski, Elżbieta Bylina, Agnieszka Woźniak, Zbigniew Nowecki, Czesław Osuch, Maciej Matłok, Tomasz Świtaj, Wanda Michej, Marek Wroński, Stanisław Głuszek, J. Kroc, Anna Nasierowska‐Guttmejer, Heikki Joensuu
2011131
7
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
The Lancet Oncology ·Antoinette R. Tan, Seock‐Ah Im, André Mattar, Rámón Colomer, Daniil Stroyakovskii, Zbigniew Nowecki, Michelino De Laurentiis, Jean‐Yves Pierga, Kyung Hae Jung, Christian Schem, Alexandra Hogea, Tanja Badovinac Črnjević, Sarah Heeson, Mahesh Shivhare, Whitney P. Kirschbrown, Eleonora Restuccia, Christian Jackisch
2020118
8
Diagnostic yield and safety of endoscopic-ultrasound guided trucut biopsy in patients with gastric submucosal tumors: a prospective study
Endoscopy ·Marcin Polkowski, W Gerke, D. Jarosz, Anna Nasierowska‐Guttmejer, Piotr Rutkowski, Zbigniew Nowecki, W. Ruka, Jarosław Reguła, E Butruk
2009114
9
Increased cancer risk of heterozygotes with NBS1 germline mutations in poland
International Journal of Cancer ·Jan Steffen, Raymonda Varon, Maria Mosor, Galina Stoyanova Maneva, Martin Maurer, Markus Stümm, Dorota Nowakowska, Maryna Rubach, Ewa Kosakowska, W. Ruka, Zbigniew Nowecki, Piotr Rutkowski, Tomasz Demkow, Małgorzata Sadowska, Mariusz Bidziński, Krzysztof Gawrychowski, Karl Sperling
2004105
10
BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).
Journal of Clinical Oncology ·Peter Schmid, Seock‐Ah Im, Anne Armstrong, (unknown), Wei‐Pang Chung, Zbigniew Nowecki, Simon Lord, Piotr J. Wysocki, Yen‐Shen Lu, Hannah Dry, Vatsala Karwe, Ross Stewart, Pia Herbolsheimer, Ana T. Nunes, Kyung Hae Jung
202184
11
Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma
Annals of Surgical Oncology ·Zbigniew Nowecki, Piotr Rutkowski, Anna Nasierowska‐Guttmejer, W. Ruka
200681
12
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer
Journal of Clinical Oncology ·Xavier Pivot, Igor Bondarenko, Zbigniew Nowecki, Mikhail Dvorkin, Ekaterina Trishkina, Jin‐Hee Ahn, Yuriy Vinnyk, Seock‐Ah Im, Tomasz Sarosiek, Sanjoy Chatterjee, Marek Z. Wojtukiewicz, Vladimir Moiseyenko, Yaroslav Shparyk, Maximino Bello, Semiglazov Vf, Sujeong Song, Jae-Yun Lim
201880
13
Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes – one institution's experience
Melanoma Research ·Zbigniew Nowecki, Piotr Rutkowski, Anna Nasierowska‐Guttmejer, W. Ruka
200373
14
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Breast Cancer Research and Treatment ·Nicholas C. Turner, Rebecca Dent, Joyce O’Shaughnessy, Sung‐Bae Kim, Steven J. Isakoff, Carlos H. Barrios, Shigehira Saji, Igor Bondarenko, Zbigniew Nowecki, Qinshu Lian, Sarah-Jayne Reilly, Heather Hinton, Matthew Wongchenko, Bruno Kovic, Aruna Mani, Mafalda Oliveira
202169
15
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
BMC Cancer ·Piotr Rutkowski, Elżbieta Bylina, Anna Klimczak, Tomasz Świtaj, Sławomir Falkowski, J. Kroc, Iwona Ługowska, Magdalena Brzeskwiniewicz, Wojciech Melerowicz, Czesław Osuch, Ewa Mierzejewska, Kacper Wasielewski, Agnieszka Woźniak, Urszula Grzesiakowska, Zbigniew Nowecki, Janusz A. Siedlecki, Janusz Limon
201264
16
The Megavoltage Radiation Therapy in Treatment of Patients With Advanced or Difficult Giant Cell Tumors of Bone
International Journal of Radiation Oncology*Biology*Physics ·W. Ruka, Piotr Rutkowski, Tadeusz Morysiński, Zbigniew Nowecki, Marcin Zdzienicki, Donata Makuła, Konrad Ptaszyński, Elżbieta Bylina, Urszula Grzesiakowska
200956
17
The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2–pT3)
Annals of Surgical Oncology ·Zbigniew Nowecki, Piotr Rutkowski, Wanda Michej
200854
18
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results
European Journal of Cancer ·Xavier Pivot, Igor Bondarenko, Zbigniew Nowecki, Mikhail Dvorkin, Ekaterina Trishkina, Jin‐Hee Ahn, Seock‐Ah Im, Tomasz Sarosiek, Sanjoy Chatterjee, Marek Z. Wojtukiewicz, Yaroslav Shparyk, Vladimir Moiseyenko, Maximino Bello, Semiglazov Vf, Young Jin Lee, Ji Hyoun Lim
201854
19
Surgery Combined With Intraoperative Brachytherapy in the Treatment of Retroperitoneal Sarcomas
Annals of Surgical Oncology ·Wirginiusz Dziewirski, Piotr Rutkowski, Zbigniew Nowecki, Maciej Sałamacha, Tadeusz Morysiński, Anna Kulik, Maria Kawczyńska, Anetta Kasprowicz, Jarosław Łyczek, W. Ruka
200645
20
211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
Annals of Oncology ·M. Martín Jiménez, Elgene Lim, (unknown), Amit Bardia, Jun Wu, Q. Zhang, Zbigniew Nowecki, F. Melo Cruz, Р. Р. Сафин, S-B. Kim, Christian Schem, Alberto J. Montero, Simran Khan, R. Bandyopadhyay, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, P.D. Pérez-Moreno, Joohyuk Sohn
202244

About Zbigniew Nowecki

Zbigniew Nowecki is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 119 papers that have together received 2.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (29 papers), HER2/EGFR in Cancer Research (28 papers), Advanced Breast Cancer Therapies (24 papers), Cutaneous Melanoma Detection and Management (23 papers), Breast Cancer Treatment Studies (20 papers), Gastrointestinal Tumor Research and Treatment (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Immunotherapy and Immune Responses (6 papers). The work is most often cited by research in Gastroenterology (689 citations), Oncology (1.5k citations), Pulmonary and Respiratory Medicine (714 citations), Cancer Research (258 citations) and Immunology (300 citations). Zbigniew Nowecki has collaborated with scholars based in Poland, United States and South Korea. Frequent co-authors include Piotr Rutkowski, W. Ruka, Anna Nasierowska‐Guttmejer, Wanda Michej, Urszula Grzesiakowska, Janusz A. Siedlecki, Wirginiusz Dziewirski, Alexander C. J. van Akkooi, Agnieszka Woźniak and Seock‐Ah Im. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Annals of Surgical Oncology, Cancer Research and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. RukaBreakdown of academic impact, for papers by Johannes H. W. de WiltBreakdown of academic impact, for papers by Amy HarlowBreakdown of academic impact, for papers by Alexander N. ShoushtariBreakdown of academic impact, for papers by Yoshikazu UenosonoBreakdown of academic impact, for papers by Frédéric ChibonBreakdown of academic impact, for papers by Iwona ŁugowskaBreakdown of academic impact, for papers by Claudia LeBreakdown of academic impact, for papers by Jaclyn F. HechtmanBreakdown of academic impact, for papers by Maria Cristina Montesco